Minalrestat  (Synonyms: ARI-509; WAY-ARI 509)

Minalrestat (ARI-509) is a potent and orally active aldose reductase inhibitor. Minalrestat can be used in the research of diabetes^[1].

Minalrestat (100 μM) decreased intracellular sorbitol without affecting intracellular glucose in primary cultured rat mesangial cells^[3].
Minalrestat (100 μM, 48 h) causes accumulation of PKC-α and -β2 in primary cultured rat mesangial cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Minalrestat (Oral gavage, 10 mg/kg/day, for 30 days) corrects the decreased microvascular reactivity in diabetic rats^[1].
Minalrestat (Oral gavage, 10 mg/kg) restores the reduced number of leukocytes adhered and migrated leukocytes in postcapillary venules in diabetic rats^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

449.20

C₁₉H₁₁BrF₂N₂O₄

129688-50-2

O=C(N1CC2=C(C=C(Br)C=C2)F)C3(CC(NC3=O)=O)C4=C(C=CC(F)=C4)C1=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Akamine EH, et al. Minalrestat, an aldose reductase inhibitor, corrects the impaired microvascular reactivity in diabetes. J Pharmacol Exp Ther. 2003 Mar;304(3):1236-42.  [Content Brief]

  [2]. Cruz JW, et al. Minalrestat and leukocyte migration in diabetes mellitus. Diabetes Metab Res Rev. 2003 May-Jun;19(3):223-31.  [Content Brief]

  [3]. Kapor-Drezgic J, et al. Effect of high glucose on mesangial cell protein kinase C-delta and -epsilon is polyol pathway-dependent. J Am Soc Nephrol. 1999 Jun;10(6):1193-203.  [Content Brief]